Alexion Pharmaceuticals Inc.’s Soliris may be the most successful rare-disease medicine in history. Its approval in multiple conditions and an annual price tag that can exceed $500,000 propelled the drug to more than $3 billion in sales last year. Now, for the first time, it looks like Alexion’s blockbuster will face serious competition. Last week, Kentucky-based Apellis Pharmaceuticals Inc. published ...

The good news is, Boeing Co. is starting to do the right things. The bad news is, it’s going to be expensive. The airplane maker said it would recommend pilots undergo flight-simulator training on its 737 Max before the embattled plane returns to service, reversing its previous stance that computer-based education would be sufficient. The Max has been grounded since ...

Australia isn’t what the world thought it was. A country that markets itself on the basis of its wide-open blue skies, azure waters and huggable wildlife is suddenly presenting a different face: Tourists in holiday towns, huddled on beaches to get away from the impending fire front; cities choked by orange smoke and falling ash; kangaroos and koalas incinerated as ...